A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/2001
11/22/2001	WO2001087810A1 Methods for the production of d-chiro-inositol and the use of d-chiro-inositol obtained therefrom
11/22/2001	WO2001087376A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
11/22/2001	WO2001087374A1 Delivery systems for treatment of vascular disease
11/22/2001	WO2001087373A1 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087372A1 Drug combinations useful for prevention of restenosis
11/22/2001	WO2001087348A2 Multifunctional nanodevice platform
11/22/2001	WO2001087343A2 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
11/22/2001	WO2001087342A2 Delivery devices for treatment of vascular disease
11/22/2001	WO2001087330A2 Compositions and methods for achieving immune suppression
11/22/2001	WO2001087328A2 Interleukin-1 inhibitors in the treatment of diseases
11/22/2001	WO2001087318A1 Phytotherapeutic composition for preventing cardiovascular diseases
11/22/2001	WO2001087312A1 Polyethylene glycol (peg) polymers for the promotion of angiogenesis
11/22/2001	WO2001087304A1 Ophthalmic solution
11/22/2001	WO2001087299A1 Aralkyl ester soft drugs
11/22/2001	WO2001087284A2 Aldosterone antagonist composition for release during aldosterone acrophase
11/22/2001	WO2001087263A2 Delivery systems for treatment of vascular disease
11/22/2001	WO2001087234A2 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers
11/22/2001	WO2001087038A2 β-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE
11/22/2001	WO2001055333A8 Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides
11/22/2001	WO2001041535A3 Eplerenone crystalline form
11/22/2001	WO2001036611A8 Process for the production of a reversibly inactive acidified plasmin composition
11/22/2001	WO2001036462A3 Protein c derivatives
11/22/2001	WO2001031036A3 Modified viral surface proteins which bind to cells of tumor vasculature
11/22/2001	WO2001030969A8 Stanniocalcin proteins and nucleic acids and methods based thereon
11/22/2001	WO2001030781A3 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
11/22/2001	WO2001027268A3 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
11/22/2001	WO2001014564A3 Polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby
11/22/2001	US20010044937 Transgenic intracytoplasmic sperm injection, retroviral gene transfer, intracytoplasmic nuclear injection, and pronuclear injection; useful as models for human disease/diagnosis, assessing safety and efficiency of drug and gene therapy
11/22/2001	US20010044544 Useful as high energy oxidizing agents in explosive and propellant formulations, and drugs for vasodilation
11/22/2001	US20010044538 Mitogen-activated protein (MAP) kinase; treating inflammatory diseases; compounds such as 3-(4-fluorophenyl)-1-hydroxy-2-(pyridin-4-yl)-1H-pyrrolo(3,2-b)pyridine
11/22/2001	US20010044537 Inhibit human factor Xa; treating thrombotic activity; 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((2-(1,2 -dihydoxyethyl)-4-hydroxy-5-ethoxytetrahydrofuran-3-yl)oxy)-pyridin-2 -yl)oxy)4-hydroxybenzamidine
11/22/2001	US20010044536 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
11/22/2001	US20010044535 Heterocyclic compounds containing a guanidine mimic, for inhibition of cell adhesion, treatment of angiogenesis disorders, inflammation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration
11/22/2001	US20010044471 Hydrogenation of racemic 6-alkoxy-1H-indene-1,2(3H)-dione-2-oxime, with chiral acid, resolution, alkylation, bromination, carboxamidation
11/22/2001	US20010044460 Ophthalmic compositions for treating ocular hypertension
11/22/2001	US20010044459 Hydroxamic acid derivatives
11/22/2001	US20010044455 Method of treatment for decreasing mortality resulting from congestive heat failure
11/22/2001	US20010044451 Tyrosine kinase inhibitors
11/22/2001	US20010044436 Bicyclic inhibitors of glycogen synthase kinase 3
11/22/2001	US20010044428 Aminopyridines and methods of using thereof
11/22/2001	US20010044110 Inhibition of mal1
11/22/2001	DE10024319A1 New bis-acylguanidine compounds are subtype-1 cellular sodium ion-proton antiporter inhibitors useful e.g. for treating arrhythmia, angina pectoris, infarction and insulin-independent diabetes mellitus
11/22/2001	DE10023485A1 New 2-((heteroaralkyl)-amino)-benzamide derivatives, are vascular endothelial growth factor (VEGF) receptors, KDR kinase and FLT kinase inhibitors useful for e.g. treating tumors, psoriasis, arthritis or renal diseases
11/22/2001	DE10023484A1 New 2-((cycloalkyl- or heterocyclyl-alkyl)-amino)-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases
11/22/2001	DE10020667A1 Neue Benzoxazin- und Benzothiazin-Derivate und deren Verwendung in Arzneimitteln New benzoxazine and benzothiazine derivatives and their use in medicaments
11/22/2001	DE10009119A1 Vertebraten Globin Vertebrate globin
11/22/2001	CA2781858A1 Modulators of tnf-.alpha. signaling
11/22/2001	CA2410091A1 Piperidyindoles as serotonin receptor ligands
11/22/2001	CA2409740A1 Novel aryl, alkenyl, and alkynyl 4-dedimethylaminotetracycline desrivatives
11/22/2001	CA2409699A1 Novel polymorph v of torasemide
11/22/2001	CA2409445A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
11/22/2001	CA2409437A1 Aldosterone antagonist composition for release during aldosterone acrophase
11/22/2001	CA2409225A1 Tricyclic pyrazole derivatives
11/22/2001	CA2409116A1 Substituted thioacetamides
11/22/2001	CA2409068A1 Novel dual oxidases as mitogenic and endocrine regulators
11/22/2001	CA2409035A1 Hydroxamic acid derivatives
11/22/2001	CA2408745A1 Anti-angiogenic polypeptides
11/22/2001	CA2408729A1 Delivery systems for treatment of vascular disease
11/22/2001	CA2408719A1 Antiproliferative drug and delivery device
11/22/2001	CA2408691A1 Compositions and methods for achieving immune suppression
11/22/2001	CA2408608A1 Antiinflammatory drug and delivery device
11/22/2001	CA2408606A1 Drug combinations useful for prevention of restenosis
11/22/2001	CA2408408A1 Modulators of tnf- alpha signaling
11/22/2001	CA2407469A1 Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
11/22/2001	CA2407258A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
11/22/2001	CA2407099A1 Aralkyl ester soft drugs
11/22/2001	CA2406013A1 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers
11/21/2001	EP1156110A2 G-protein coupled receptor (HFGAN72Y)
11/21/2001	EP1156054A1 Drugs containing phosphoric acid derivatives as the active ingredient
11/21/2001	EP1156049A1 Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them
11/21/2001	EP1156039A1 Pyridazin-3-one derivatives and medicines containing the same
11/21/2001	EP1155693A1 Intermittent claudication remedies
11/21/2001	EP1155691A2 Anti-angiogenic compositions and methods of use
11/21/2001	EP1155690A2 Anti-angiogenic compositions and method of use
11/21/2001	EP1155689A2 Anti-angiogenic compositions and methods of use
11/21/2001	EP1155021A1 Hesperitin pro-forms with enhanced bioavailability
11/21/2001	EP1155015A1 Process for the production of tert-butyl (e)-(6-[2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl](4r,6s)-2,2-dimethyl[1,3]dioxan-4-yl)acetate
11/21/2001	EP1155007A2 1,2-benzothiazepines for the treatment of hyperlipidemic diseases
11/21/2001	EP1155003A1 Novel guanidine derivatives as inhibitors of cell adhesion
11/21/2001	EP1155000A1 2-aminopyridines containing fused ring substituents
11/21/2001	EP1154988A1 Mevinolin derivatives
11/21/2001	EP1154983A1 Novel substituted 3-phenoxy and 3-phenylalkyloxy-2-phenyl-propylamines
11/21/2001	EP1154801A1 Integration of transplanted neural progenitor cells into neural tissue of immature and mature dystrophic recipients
11/21/2001	EP1154785A2 Inhibitors for use in hemostasis and immune function
11/21/2001	EP1154777A1 Medicament for treating hypertension
11/21/2001	EP1154774A1 Quinazoline derivatives as angiogenesis inhibitors
11/21/2001	EP1154769A1 A novel anti-angiogenic agent comprising at least one kringle region and an upstream pre-activation domain of plasminogen
11/21/2001	EP1154767A1 Substituted stilbene compounds with vascular damaging activity
11/21/2001	EP1154764A1 Epoxide hydrolase complexes and methods therewith
11/21/2001	EP1049721B1 Synthetic polysaccharides, their method of production and pharmaceutical compositions containing same
11/21/2001	EP1007085B1 Use of growth hormone in compositions for treating insulin resistance in the heart
11/21/2001	EP0952974B1 Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharmaceutical and cosmetic compositions containing same
11/21/2001	EP0914319B1 Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
11/21/2001	EP0873340B1 Heterocyclic substituted cyclopentane compounds
11/21/2001	EP0833638B1 USE OF IMIDAZO 1,5-a]QUINOLONES AS NEUROPROTECTIVE AGENTS
11/21/2001	EP0832082B1 N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
11/21/2001	EP0831910B1 Epoxy-steroidal aldosterone antagonist and angiotensin ii antagonist combination therapy for treatment of congestive heart failure
11/21/2001	EP0745081B1 indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase
11/21/2001	CN1323344A DNA zyme and method for treating restenosis
11/21/2001	CN1323314A Inhibitors of caspases

1 ... 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 ... 1595